Recent Peer Reviewed Publications

• 1. Rick AM
  2. Laurens MB
  3. Huang Y
  4. Yu C
  5. Martin TCS
  6. Rodriguez CA
  7. Rostad CA
  8. Maboa RM
  9. Baden LR
  10. El Sahly HM
  11. Grinsztejn B
  12. Gray GE
  13. Gay CL
  14. Gilbert PB
  15. Janes HE
  16. Kublin JG
  17. Huang Y
  18. Leav B
  19. Hirsch I
  20. Struyf F
  21. Dunkle LM
  22. Neuzil KM
  23. Corey L
  24. Goepfert PA
  25. Walsh SR
  26. Follmann D
  27. Kotloff KL
  Risk of COVID-19 after natural infection or vaccination.; EBioMedicine; Vol 96, pp. 104799. 2023 Sep 20.
• 1. Rouphael N
  2. Winokur P
  3. Keefer MC
  4. Traenkner J
  5. Drobeniuc A
  6. Doi Y
  7. Munsiff S
  8. Fowler VG
  9. Evans S
  10. Oler RE
  11. Tuyishimire B
  12. Lee M
  13. Ghazaryan V
  14. Chambers HF
  Daily fosfomycin versus levofloxacin for complicated urinary tract infections.; mBio. 2023 Sep 12.
• 1. Branche AR
  2. Rouphael NG
  3. Diemert DJ
  4. Falsey AR
  5. Losada C
  6. Baden LR
  7. Frey SE
  8. Whitaker JA
  9. Little SJ
  10. Anderson EJ
  11. Walter EB
  12. Novak RM
  13. Rupp R
  14. Jackson LA
  15. Babu TM
  16. Kottkamp AC
  17. Luetkemeyer AF
  18. Immergluck LC
  19. Presti RM
  20. Bäcker M
  21. Winokur PL
  22. Mahgoub SM
  23. Goepfert PA
  24. Fusco DN
  25. Malkin E
  26. Bethony JM
  27. Walsh EE
  28. Graciaa DS
  29. Samaha H
  30. Sherman AC
  31. Walsh SR
  32. Abate G
  33. Oikonomopoulou Z
  34. El Sahly HM
  35. Martin TCS
  36. Kamidani S
  37. Smith MJ
  38. Ladner BG
  39. Porterfield L
  40. Dunstan M
  41. Wald A
  42. Davis T
  43. Atmar RL
  44. Mulligan MJ
  45. Lyke KE
  46. Posavad CM
  47. Meagher MA
  48. Stephens DS
  49. Neuzil KM
  50. Abebe K
  51. Hill H
  52. Albert J
  53. Telu K
  54. Mu J
  55. Lewis TC
  56. Giebeig LA
  57. Eaton A
  58. Netzl A
  59. Wilks SH
  60. Türeli S
  61. Makhene M
  62. Crandon S
  63. Montefiori DC
  64. Makowski M
  65. Smith DJ
  66. Nayak SU
  67. Roberts PC
  68. Beigel JH
  Comparison of bivalent and monovalent SARS-CoV-2 variant vaccines: the phase 2 randomized open-label COVAIL trial.; Nature medicine. 2023 Aug 28.
• 1. Rouphael NG
  2. Branche AR
  3. Diemert DJ
  4. Falsey AR
  5. Losada C
  6. Baden LR
  7. Frey SE
  8. Whitaker JA
  9. Little SJ
  10. Kamidani S
  11. Walter EB
  12. Novak RM
  13. Rupp R
  14. Jackson LA
  15. Babu TM
  16. Kottkamp AC
  17. Luetkemeyer AF
  18. Immergluck LC
  19. Presti RM
  20. Bäcker M
  21. Winokur PL
  22. Mahgoub SM
  23. Goepfert PA
  24. Fusco DN
  25. Atmar RL
  26. Posavad CM
  27. Netzl A
  28. Smith DJ
  29. Telu K
  30. Mu J
  31. McQuarrie LJ
  32. Makowski M
  33. Makhene MK
  34. Crandon S
  35. Montefiori DC
  36. Roberts PC
  37. Beigel JH
  Immunogenicity of a Two Dose Regimen of Moderna mRNA Beta/Omicron BA.1 Bivalent Variant Vaccine Boost in a Randomized Clinical Trial.; The Journal of infectious diseases. 2023 Aug 10.
• 1. de Bruyn G
  2. Wang J
  3. Purvis A
  4. Ruiz MS
  5. Adhikarla H
  6. Alvi S
  7. Bonaparte MI
  8. Brune D
  9. Bueso A
  10. Canter RM
  11. Ceregido MA
  12. Deshmukh S
  13. Diemert D
  14. Finn A
  15. Forrat R
  16. Fu B
  17. Gallais J
  18. Griffin P
  19. Grillet MH
  20. Haney O
  21. Henderson JA
  22. Koutsoukos M
  23. Launay O
  24. Torres FM
  25. Masotti R
  26. Michael NL
  27. Park J
  28. Rivera-Medina DM
  29. Romanyak N
  30. Rook C
  31. Schuerman L
  32. Sher LD
  33. Tavares-Da-Silva F
  34. Whittington A
  35. Chicz RM
  36. Gurunathan S
  37. Savarino S
  38. Sridhar S
  Safety and immunogenicity of a variant-adapted SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant as a booster in adults primed with authorized vaccines: a phase 3, parallel-group study.; EClinicalMedicine; Vol 62, pp. 102109. 2023 Jul 22.
• 1. Falsey AR
  2. Walsh EE
  Respiratory syncytial virus Prefusion F vaccine.; Cell; Vol 186(15), pp. 3137-3137.e1. 2023 Jul 20.
• 1. Lyke KE
  2. Atmar RL
  3. Dominguez Islas C
  4. Posavad CM
  5. Deming ME
  6. Branche AR
  7. Johnston C
  8. El Sahly HM
  9. Edupuganti S
  10. Mulligan MJ
  11. Jackson LA
  12. Rupp RE
  13. Rostad CA
  14. Coler RN
  15. Bäcker M
  16. Kottkamp AC
  17. Babu TM
  18. Dobrzynski D
  19. Martin JM
  20. Brady RC
  21. Frenck RW
  22. Rajakumar K
  23. Kotloff K
  24. Rouphael N
  25. Szydlo D
  26. PaulChoudhury R
  27. Archer JI
  28. Crandon S
  29. Ingersoll B
  30. Eaton A
  31. Brown ER
  32. McElrath MJ
  33. Neuzil KM
  34. Stephens DS
  35. Post DJ
  36. Lin BC
  37. Serebryannyy L
  38. Beigel JH
  39. Montefiori DC
  40. Roberts PC
  Immunogenicity of NVX-CoV2373 heterologous boost against SARS-CoV-2 variants.; NPJ vaccines; Vol 8(1), pp. 98. 2023 Jul 11.
• 1. Theodore DA
  2. Branche AR
  3. Zhang L
  4. Graciaa DS
  5. Choudhary M
  6. Hatlen TJ
  7. Osman R
  8. Babu TM
  9. Robinson ST
  10. Gilbert PB
  11. Follmann D
  12. Janes H
  13. Kublin JG
  14. Baden LR
  15. Goepfert P
  16. Gray GE
  17. Grinsztejn B
  18. Kotloff KL
  19. Gay CL
  20. Leav B
  21. Miller J
  22. Hirsch I
  23. Sadoff J
  24. Dunkle LM
  25. Neuzil KM
  26. Corey L
  27. Falsey AR
  28. El Sahly HM
  29. Sobieszczyk ME
  30. Huang Y
  Clinical and Demographic Factors Associated With COVID-19, Severe COVID-19, and SARS-CoV-2 Infection in Adults: A Secondary Cross-Protocol Analysis of 4 Randomized Clinical Trials.; JAMA network open; Vol 6(7), pp. e2323349. 2023 Jul 03.
• 1. Falsey AR
  2. Branche AR
  3. Croft DP
  4. Formica MA
  5. Peasley MR
  6. Walsh EE
  Real-Life Assessment of BioFire FilmArray® Pneumonia Panel in Adults Hospitalized with Respiratory Illness.; The Journal of infectious diseases. 2023 Jun 27.
• 1. Rouphael NG
  2. Branche AR
  3. Diemert DJ
  4. Falsey AR
  5. Losada C
  6. Baden LR
  7. Frey SE
  8. Whitaker JA
  9. Little SJ
  10. Kamidani S
  11. Walter EB
  12. Novak RM
  13. Rupp R
  14. Jackson LA
  15. Babu TM
  16. Kottkamp AC
  17. Luetkemeyer AF
  18. Immergluck LC
  19. Presti RM
  20. Bäcker M
  21. Winokur PL
  22. Mahgoub SM
  23. Goepfert PA
  24. Fusco DN
  25. Atmar RL
  26. Posavad CM
  27. Netzl A
  28. Smith DJ
  29. Telu K
  30. Mu J
  31. Makowski M
  32. Makhene MK
  33. Crandon S
  34. Montefiori DC
  35. Roberts PC
  36. Beigel JH
  Immunogenicity of a Two Dose Regimen of Moderna mRNA Beta/Omicron BA.1 Bivalent Variant Vaccine Boost in a Randomized Clinical Trial.; medRxiv : the preprint server for health sciences. 2023 Jun 10.
• 1. Ortega-Villa AM
  2. Hynes NA
  3. Levine CB
  4. Yang K
  5. Wiley Z
  6. Jilg N
  7. Wang J
  8. Whitaker JA
  9. Colombo CJ
  10. Nayak SU
  11. Kim HJ
  12. Iovine NM
  13. Ince D
  14. Cohen SH
  15. Langer AJ
  16. Wortham JM
  17. Atmar RL
  18. El Sahly HM
  19. Jain MK
  20. Mehta AK
  21. Wolfe CR
  22. Gomez CA
  23. Beresnev T
  24. Mularski RA
  25. Paules CI
  26. Kalil AC
  27. Branche AR
  28. Luetkemeyer A
  29. Zingman BS
  30. Voell J
  31. Whitaker M
  32. Harkins MS
  33. Davey RT
  34. Grossberg R
  35. George SL
  36. Tapson V
  37. Short WR
  38. Ghazaryan V
  39. Benson CA
  40. Dodd LE
  41. Sweeney DA
  42. Tomashek KM
  Evaluating Demographic Representation in Clinical Trials: Use of the Adaptive Coronavirus Disease 2019 Treatment Trial (ACTT) as a Test Case.; Open forum infectious diseases; Vol 10(6), pp. ofad290. 2023 May 27.
• 1. Ince D
  2. Fiawoo S
  3. Choudhury R
  4. Cosgrove SE
  5. Dobrzynski D
  6. Gold H
  7. Lee JH
  8. Percival KM
  9. Shulder S
  10. Sony D
  11. Spivak ES
  12. Tamma PD
  13. Nori P
  Epidemiology of Gram-Negative Bloodstream Infections in the United States: Results From a Cohort of 24 Hospitals.; Open forum infectious diseases; Vol 10(7), pp. ofad265. 2023 May 22.
• 1. Ramirez J
  2. Carrico R
  3. Wilde A
  4. Junkins A
  5. Furmanek S
  6. Chandler T
  7. Schulz P
  8. Hubler R
  9. Peyrani P
  10. Liu Q
  11. Trivedi S
  12. Uppal S
  13. Kalina WV
  14. Falsey AR
  15. Walsh EE
  16. Yacisin K
  17. Jodar L
  18. Gessner BD
  19. Begier E
  Diagnosis of Respiratory Syncytial Virus in Adults Substantially Increases When Adding Sputum, Saliva, and Serology Testing to Nasopharyngeal Swab RT-PCR.; Infectious diseases and therapy; Vol 12(6), pp. 1593-1603. 2023 May 06.
• 1. Goodkin K
  2. Evering TH
  3. Anderson AM
  4. Ragin A
  5. Monaco CL
  6. Gavegnano C
  7. Avery RJ
  8. Rourke SB
  9. Cysique LA
  10. Brew BJ
  The comorbidity of depression and neurocognitive disorder in persons with HIV infection: call for investigation and treatment.; Frontiers in cellular neuroscience; Vol 17, pp. 1130938. 2023 Apr 28.
• 1. Stieh DJ
  2. Barouch DH
  3. Comeaux C
  4. Sarnecki M
  5. Stephenson KE
  6. Walsh SR
  7. Sawant S
  8. Heptinstall J
  9. Tomaras GD
  10. Kublin JG
  11. McElrath MJ
  12. Cohen KW
  13. De Rosa SC
  14. Alter G
  15. Ferrari G
  16. Montefiori D
  17. Mann P
  18. Nijs S
  19. Callewaert K
  20. Goepfert PA
  21. Edupuganti S
  22. Karita E
  23. Seaman MS
  24. Corey L
  25. Baden LR
  26. Pau MG
  27. Schuitemaker H
  28. Tomaka F
  Safety and Immunogenicity of Ad26-Vectored HIV Vaccine With Mosaic Immunogens and a Novel Mosaic Envelope Protein in HIV-Uninfected Adults: A Phase 1/2a Study.; The Journal of infectious diseases; Vol 227(8), pp. 939-950. 2023 Apr 18.